Stockreport

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

Lyell Immunopharma, Inc.  (LYEL) 
PDF Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate with strong Phase 1 clinic [Read more]